Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBenjamin HébraudAPAurore PerrotLMLudovic Martinet

Discussion

Loading...

Member takes

Overview

Longitudinal analysis reveals immune remodeling patterns impact treatment response in multiple myeloma, suggesting strategies to address resistance.

Key Points

  • Response to teclistamab links with pre-existing lymphoid-rich microenvironment in bone marrow, enhancing cytotoxic activity.
  • Baseline immune landscapes show T cell and NK cell depletion in primary resistance cases, highlighting immunosuppressive environments.
  • Longitudinal monitoring indicates T cell dynamics in peripheral blood correspond with treatment outcomes for multiple myeloma.
  • Findings emphasize the importance of immune remodeling in predicting therapeutic responses and developing resistance strategies.

Cite This Study

Hébraud et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc8bhttps://doi.org/10.1182/blood-2025-918
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  2. 2Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy2025
  3. 3Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  4. 4Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma2025
  5. 5Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience2025